Wall Street Zen upgraded shares of Iambic Therapeutics (NASDAQ:IAM – Free Report) to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
Iambic Therapeutics Stock Down 12.6%
NASDAQ IAM opened at $10.17 on Friday. Iambic Therapeutics has a one year low of $9.60 and a one year high of $25.00.
Insider Buying and Selling
In related news, Director Evan Lockwood Rachlin acquired 718,750 shares of the stock in a transaction on Friday, October 16th. The shares were acquired at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the transaction, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. The trade was a 38.45% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.90% of the company’s stock.
Iambic Therapeutics Company Profile
See Also
- Five stocks we like better than Iambic Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
